article thumbnail

Tech Moves: Adaptive Biotechnologies COO departing; Sana adds leaders; and more

GeekWire

Adaptive Photo) — Mark Adams is stepping down as chief operating officer of Adaptive Biotechnologies , the company said today in a regulatory filing. ” Adams was previously managing director of healthcare advanced analytics at SVB Securities and was a principal at Booz Allen Hamilton. . Mark Adams.

article thumbnail

Sana Biotechnology will cut 15% of its workforce in latest layoffs affecting Seattle companies

GeekWire

Seattle-based cell and gene therapy company Sana Biotechnology will reduce its workforce by 15%, according to a statement issued Tuesday. million in cash, cash equivalents, and marketable securities on hand. Adaptive Biotechnologies , Absci , and Zymeworks also announced layoffs this year. Sana CEO Steve Harr. Sana Photo).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Adaptive Biotechnologies lays off about 100 people, 12% of headcount, to ‘streamline our workforce’

GeekWire

Chad Robins, left, is co-founder and CEO of Adaptive Biotechnologies, which he co-founded with his brother, Harlan Robins, right, the company’s chief scientific officer. Adaptive Biotechnologies Photo). Adaptive Biotechnologies is laying off 12% of its workforce, or about 100 employees, GeekWire has learned. “We

article thumbnail

Sana Biotechnology files to go public, looks to cure disease by modifying genes in the body

GeekWire

Less than three years after it was founded and with no revenue on the books, Sana Biotechnology has f iled to go public. It reported $459 million in cash, cash equivalents and marketable securities at the end of September 2020. And like many biotechnology companies it is losing money. Sana CEO Steve Harr (Sana photo).

article thumbnail

Adaptive Biotechnologies revenue rises 57% in 2021 to $154.3M

GeekWire

Adaptive Biotechnologies , which develops technology to assess the immune response, posted $154.3 million available in cash, cash equivalents and marketable securities. Adaptive moved into its new headquarters in September. Co-founders Harlan (left) and Chad Robins on the new plaza. GeekWire Photo / Charlotte Schubert).

article thumbnail

Sana Biotechnology boosts IPO range, looks to raise $517 million

GeekWire

Sana Biotechnology — the Seattle upstart that’s looking to treat a variety of diseases through gene therapy and cell engineering — is generating buzz on Wall Street. That would net the biotechnology company $517 million if it sold at the midpoint of that range. Sana’s technology (screen grab via IPO filing).

article thumbnail

Vancouver, Wash. biotech company Absci files to go public

GeekWire

Securities and Exchange Commission. The company, founded in 2011, began commercial operations in 2018 and now has partnerships with Merck, Xyphos Biotechnology, Alpha Cancer Technologies and several other drug companies. 2020 revenue was $4.7 million, up from $2 million for 2019.

Company 134